HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NRXP), Tuesday announced an agreement to purchase the Kadima Neuropsychiatry Institute, a California-based interventional psychiatry clinic. The financial details of the transaction have not been disclosed.
Following the acquisition, Kadima Neuropsychiatry is expected to serve as clinical model for Hope treatment offerings nationwide, including psychedelic medications, transcranial magnetic stimulation, and hyperbaric therapy.
Upon closing of the acquisition, David Feifel, Founder and Medical Director of Kadima, will join HOPE as its first Chief Medical Innovation Officer.
The deal is estimated to be accretive to revenue and EBITDA for NRx and HOPE.
In the pre-market hours, NRx's stock is trading at $2.02, down 2.88 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.